BƯỚC ĐẦU ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ LỌC MÁU HẤP PHỤ KHÁNG THỂ Ở BỆNH NHÂN GUILLAIN BARRÉ

Abstract

Objective: Guillain Barré syndrome is a common neuro-immune disease that can cause many sequelae. There are many treatments for this syndrome with the goal of speeding up recovery, minimizing sequelae, in which antibody-adsorbent hemofiltration has been widely applied and proven effective. This study aims to evaluate the results of antibody-adsorbent hemofiltration in the treatment on patients with Guillain Barré. Method: a prospective interventional study, data was collected on all patients diagnosed with Guillain Barré syndrome who were treated by imminoadsorption during the period from September 2022 to August 2023. Clinical indicator which use the Hughes grades were evaluted before and after immonoadsorption. Result:  23 patients were inrolved in this study,in which  male/female ratio was 3:2, mean age: 55.4 ± 13.9 years old and received average  4.4. ±0.72 times for adsorption. Immunoadsorption was effective in improveing the Hughes score (4.3±0.45 versus 2.8±1.25, p=0.000). Conclusion: The  Immunoadsorption improves the level of loss of mobility as shown by the Hughes score in Guillain barré patients, especially in the group of patients with single electromyographic changes.